GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AlloVir Inc (NAS:ALVR) » Definitions » Debt-to-EBITDA

AlloVir (AlloVir) Debt-to-EBITDA : -0.16 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is AlloVir Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

AlloVir's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $10.78 Mil. AlloVir's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $16.65 Mil. AlloVir's annualized EBITDA for the quarter that ended in Dec. 2023 was $-174.78 Mil. AlloVir's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.16.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for AlloVir's Debt-to-EBITDA or its related term are showing as below:

ALVR' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.44   Med: -0.18   Max: -0.12
Current: -0.15

During the past 6 years, the highest Debt-to-EBITDA Ratio of AlloVir was -0.12. The lowest was -0.44. And the median was -0.18.

ALVR's Debt-to-EBITDA is ranked worse than
100% of 276 companies
in the Biotechnology industry
Industry Median: 1.37 vs ALVR: -0.15

AlloVir Debt-to-EBITDA Historical Data

The historical data trend for AlloVir's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AlloVir Debt-to-EBITDA Chart

AlloVir Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial -0.44 -0.12 -0.18 -0.21 -0.15

AlloVir Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.22 -0.20 -0.17 -0.18 -0.16

Competitive Comparison of AlloVir's Debt-to-EBITDA

For the Biotechnology subindustry, AlloVir's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AlloVir's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AlloVir's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where AlloVir's Debt-to-EBITDA falls into.



AlloVir Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

AlloVir's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(10.781 + 16.648) / -180.933
=-0.15

AlloVir's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(10.781 + 16.648) / -174.78
=-0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


AlloVir  (NAS:ALVR) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


AlloVir Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of AlloVir's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


AlloVir (AlloVir) Business Description

Traded in Other Exchanges
N/A
Address
1100 Winter Street, Waltham, MA, USA, 02451
AlloVir Inc is a late clinical-stage cell therapy company. It is developing allogeneic T-cell therapies to treat and prevent devastating viral diseases. The firm's pipeline includes ALVR106, ALVR109, ALVR108, and others. The company's product candidate, Viralym-M, is a multi-VST therapy targeting five viruses namely BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6.
Executives
Vikas Sinha director, 10 percent owner, officer: See Remarks C/O ALEXION PHARMACUETICALS, INC., 352 KNOTTER DRIVE, CHESHIRE CT 06410
Diana Brainard director C/O ALLOVIR, INC., 139 MAIN STREET, SUITE 500, CAMBRIDGE MA 02142
Edward Miller officer: General Counsel C/O ALEXION PHARMACEUTICALS, INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Brett R Hagen officer: Chief Accounting Officer 200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Gilead Sciences Inc 10 percent owner 333 LAKESIDE DR, FOSTER CITY CA 94404
Cintia Piccina officer: Chief Commercial Officer 60 JUBILEE AVENUE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 X0 OX14 4R
Derek N. Adams director ALLOVIR, INC., 1100 WINTER STREET, WALTHAM MA 02451
Van Beek Jeroen B officer: Chief Commercial Officer C/O TRICIDA, INC., 7000 SHORELINE COURT, SUITE 201, SOUTH SAN FRANCISCO CA 94080
Ercem Atillasoy officer: See Remarks C/O ALLOVIR, INC., 139 MAIN STREET, SUITE 500, CAMBRIDGE MA 02142
David Hallal director, 10 percent owner, officer: Chief Executive Officer C/O ALEXION PHARMACEUTICALS, INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
F2 - Tpo Investments Llc director, 10 percent owner C/O SINGER, MCKEON INC., 8 W 38TH ST SUITE 1001, NEW YORK NY 10018
F2 Bioscience Av 2022 Llc director, 10 percent owner 8 WEST 38TH STREET, SUITE 1001, NEW YORK NY 10018
Capital I 2020 F2 director, 10 percent owner 8 WEST 38TH STREET, SUITE 1001, NEW YORK NY 10018
F2 Mc, Llc director, 10 percent owner 8 WEST 38TH STREET, SUITE 1001, NEW YORK NY 10018
Globeways Holdings Ii Ltd director, 10 percent owner C/O SINGER, MCKEON INC., 8 W 38TH ST. STE. 1001, NEW YORK NY 10018